Medeor Therapeutics Raises $57 Million In Series B Financing
This financing will support the Phase 3 clinical trial of MDR-101 in living donor HLA-matched kidney transplant patients, being conducted under a Special Protocol Agreement with the
"Organ transplantation is one of the most remarkable life-giving feats of modern medicine, though patients must deal with intense and sometimes intolerable chronic immune suppression," said
"
"Since Medeor's inception, we have worked to bring our potentially transformative programs to the point of pivotal clinical trials," said
About
Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients.
About
About
Founded in 1974, Sofinnova specializes in clinical and late preclinical investments in biopharmaceutical products. Our goal is to actively partner with entrepreneurs across all stages of company development. We seek to build world class companies that aspire to dramatically improve the current state of medical care and the lives of patients through bringing innovative products to market. For more information, please visit www.sofinnova.com.
Contact
Chief Financial and Business Officer
mplunkett@medeortherapeutics.com
View original content:http://www.prnewswire.com/news-releases/medeor-therapeutics-raises-57-million-in-series-b-financing-300561638.html
SOURCE


Missing American Military Personnel Identified After Plane Crash
Analysis Group Welcomes New Affiliates, Announces Consultant Promotions
Advisor News
- Survey: Most Americans still feel prosperous despite economic worries
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
More Advisor NewsAnnuity News
- AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
More Annuity NewsHealth/Employee Benefits News
- States push short-term insurance as healthcare costs climb
- WYDEN, SANDERS, SENATE DEMOCRATS CALL OUT INSURANCE COMPANY COLLUSION WITH TRUMP ADMINISTRATION TO KICK THOUSANDS OF AMERICANS OFF HEALTH INSURANCE
- WYDEN STATEMENT ON FINANCE COMMITTEE DEMOCRATIC MAJORITY AGENDA
- Health insurance switch costs city
- New LTC solutions fill a critical gap for clients
More Health/Employee Benefits NewsLife Insurance News
- AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
- AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
- AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
- AM Best Upgrades Credit Ratings of CTBC Insurance Company Ltd
- AM Best Affirms Credit Ratings of NongHyup Property and Casualty Insurance Company Limited
More Life Insurance News